Zhu et al. developed a stratification system based on two immune-related ovarian cancer-derived exosome signatures, identifying PSMA2 as a risk factor in immunotherapy treatment for ovarian cancer patients [18]. This evidence concerns the gene PSMA2 and ovarian carcinoma.